Ranked by engagement
Top topics — all time page 10
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 10 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: What pooling buys you and what it destroys
On the subject in the title: Revisiting: What pooling buys you and what it destroys Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
|
+97 | 107 | 4k | 19h |
|
How the vendor documentation pages are maintained, and by whom — what changed since
Asking directly, because I could not find a straight answer: How the vendor documentation pages are maintained, and by whom — what changed since A logistics question, since the answers here are usually better…
|
+98 | 104 | 3k | 8mo |
|
Molecular mass of semaglutide and why the figure differs between sources — does this still hold?
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 (…
|
+94 | 102 | 14k | 19mo |
|
Reading order for a first week here, and what to skip until later — what changed since
Reading order for a first week here, and what to skip until later — what changed since Writing it up because I had to work it out twice and would rather nobody else did. I want to check my reasoning rather…
|
+89 | 93 | 28k | 4h |
|
Pen dose counters: what a click does and does not guarantee
On the subject in the title: Pen dose counters: what a click does and does not guarantee Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking…
|
+116 | 122 | 1.6k | 8mo |
|
[2026 update] Clearance pathways and what renal impairment changes
On the subject in the title: Clearance pathways and what renal impairment changes Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front…
|
+63 | 69 | 50k | 13mo |
|
[2026 update] Does a peptide degrade silently, with no visual change?
Does a peptide degrade silently, with no visual change? — that is the question, and I have not found it answered plainly anywhere I have looked. I have read the maintained page on this and I still have a gap,…
|
+82 | 86 | 24k | 15d |
|
Pregnancy as an absolute contraindication
Pregnancy as an absolute contraindication — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in this class mostly…
|
+102 | 106 | 21k | 14mo |
|
[2026 update] Confounding by indication, explained with a concrete example
Confounding by indication, explained with a concrete example Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
|
+103 | 116 | 22k | 5mo |
|
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since
Posting this under the heading it deserves: A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Everything below is what sits behind that. I have read the maintained page on this and I…
|
+86 | 93 | 25k | 13mo |
|
Managing an unplanned gap in supply
Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the answer.…
|
+105 | 110 | 5.1k | 3mo |
|
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…
|
+100 | 108 | 1.3k | 8mo |
|
Follow-up: Tracking intake honestly when appetite is absent
Tracking intake honestly when appetite is absent Writing it up because I had to work it out twice and would rather nobody else did. Longitudinal report with the method stated, because a number without a…
|
+94 | 106 | 1.8k | 13mo |
|
Tracking intake honestly when appetite is absent
On the subject in the title: Tracking intake honestly when appetite is absent Working notes rather than a conclusion. Longitudinal report with the method stated, because a number without a method is not a…
|
+109 | 115 | 4.8k | 20h |
|
Pregnancy and pregnancy planning: contraindication and washout
Posting this under the heading it deserves: Pregnancy and pregnancy planning: contraindication and washout Everything below is what sits behind that. General question, not a request for advice about my own…
|
+111 | 122 | 2.4k | 3mo |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies
Older adults, sarcopenia risk, and the trade-off nobody quantifies — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…
|
+103 | 109 | 12k | 5mo |
|
Angle of injection and whether 90 degrees is always right
On the subject in the title: Angle of injection and whether 90 degrees is always right Working notes rather than a conclusion. Reporting something rather than asking about it, in case the pattern is useful to…
|
+105 | 116 | 5.4k | 4mo |
|
Follow-up: Dead volume across syringe and needle combinations
Dead volume across syringe and needle combinations — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how quickly these go…
|
+81 | 98 | 22k | 18mo |
|
[2026 update] Antibiotics and a course of something with delayed emptying
On the subject in the title: Antibiotics and a course of something with delayed emptying Working notes rather than a conclusion. Reporting something rather than asking about it, in case the pattern is useful…
|
+88 | 97 | 19k | 13h |
|
Second pass at: Triple agonism: additive, synergistic, or neither?
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…
|
+114 | 120 | 1.4k | 10mo |
|
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
|
+104 | 114 | 10k | 12mo |
|
What we do not know about retatrutide, listed explicitly
The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024) with SURMOUNT-OSA…
|
+106 | 113 | 4.8k | 17mo |
|
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
|
+72 | 81 | 44k | 1d |
|
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
+64 | 70 | 52k | 17d |
|
Revisiting: A page that has drifted out of date and needs a maintainer
Revisiting: A page that has drifted out of date and needs a maintainer Writing it up because I had to work it out twice and would rather nobody else did. Nominating something for promotion into the…
|
+112 | 119 | 8.8k | 5mo |
|
Reading order for a first week here, and what to skip until later
Reading order for a first week here, and what to skip until later Writing it up because I had to work it out twice and would rather nobody else did. I want to check my reasoning rather than get a conclusion.…
|
+112 | 117 | 3.1k | 15mo |
|
Splitting a vial for two laboratories: how to do it without ruining both — what changed since
Posting this under the heading it deserves: Splitting a vial for two laboratories: how to do it without ruining both — what changed since Everything below is what sits behind that. A logistics question, since…
|
+107 | 115 | 5.2k | 22mo |
|
Comparing prices across jurisdictions without misleading yourself
Comparing prices across jurisdictions without misleading yourself — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…
|
+78 | 83 | 33k | 1mo |
|
The CagriSema phase 2 paper and what a fixed combination buys
Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
|
+88 | 93 | 29k | 11mo |
|
What I would want from a home test that does not exist yet — what changed since
Asking directly, because I could not find a straight answer: What I would want from a home test that does not exist yet — what changed since Posting the method first, because I know what the first three…
|
+101 | 111 | 1.9k | 21h |